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Pathology, clinical care teams, and public health experts often operate in silos.
We hypothesized that large data sets from laboratories when integrated with
other healthcare data can provide evidence that can be used to optimize
planning for healthcare needs, often driven by health-seeking or delivery
behavior. From the hospital information system, we extracted raw data from
tests performed from 2019 to 2021, prescription drug usage, and admission
patterns from pharmacy and nursing departments during the COVID-19
pandemic in Kenya (March 2020 to December 2021). Proportions and rates
were calculated. Regression models were created, and a t-test for differences
between means was applied for monthly or yearly clustered data compared to
pre-COVID-19 data. Tests for malaria parasite, Mycobacterium tuberculosis,
rifampicin resistance, blood group, blood count, and histology showed a
statistically signiﬁcant decrease in 2020, followed by a partial recovery in 2021.
This pattern was attributed to restrictions implemented to control the spread of
COVID-19. On the contrary, D-dimer, ﬁbrinogen, CRP, and HbA1c showed a
statistically signiﬁcant increase (p-value <0.001). This pattern was attributed
to increased utilization related to the clinical management of COVID-19.
Prescription drug utilization revealed a non-linear relationship to the COVID19 positivity rate. The results from this study reveal the expected scenario in
the event of similar outbreaks. They also reveal the need for increased efforts
at diabetes and cancer screening, follow-up of HIV, and tuberculosis patients.
To realize a broader healthcare impact, pathology departments in Africa should
invest in integrated data analytics, for non-communicable diseases as well.
KEYWORDS

integrated data, pathology, pharmacy, laboratory, nursing, epidemiology, COVID-19,
Kenya
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Introduction

β-lactams, macrolides, fluoroquinolones, glucocorticoids;
dexamethasone, prednisolone, and methylprednisolone were
used especially for moderate and severe COVID-19 (14).
Newly designed or repurposed therapeutics to treat severely
ill COVID-19 patients were quickly adopted or as soon
as clinical trials reporting variable degrees of efficacy were
reported: monoclonal antibodies; SARS-CoV-2 neutralizing
types, and anti-inflammatory types such as tocilizumab, an
anti-interleukin-6 (IL-6) receptor antibody, and remdesivir,
an antiviral agent (15, 16). In Kenya, remdesivir became
available around June 2020. Tocilizumab had been in use for
the treatment of severe rheumatoid arthritis; its use, however,
increased significantly with the pandemic, perhaps also because
our institution was a study site for the EMPACTA trial which
evaluated the efficacy of tocilizumab in hospitalized patients
with COVID-19 pneumonia (17).
Closely related to therapeutics was the unmet need for
in-patient care. This includes not just intensive care unit
(ICU) beds but also increased demand for intensivists,
nursing care, and personal protective equipment (7, 18, 19).
And, all this in a background of other communicable and
NCDs, medical and surgical healthcare needs, that now
had to be conducted with heightened infection control
protocols. In this volatile public health climate, data and
indicators related to the pandemic such as positivity
rate, incidence rates, clinical trials hospitalization rates,
case-fatality ratio, and vaccination coverage published in
publicly available national or global platforms proved to be
extremely useful for both patient treatment and policy or
guideline making.
Having experienced numerous healthcare delivery
challenges caused by the pandemic, we sought to identify
evidence-based tools that may be useful for healthcare planning
at an institutional level. We become aware that, although a large
amount of data has been captured in the institutional healthcare
information systems, analysis of these data for evidencebased planning was lagging. Pathology and epidemiology
data appeared to be central; however, an integrated approach
encompassing data from clinical care teams, pharmacies, and
therapeutics promised greater insights. In addition, guidelines
or policies based on global data required contextualizing
using local data for meaningful local interventions, not to
mention that institutional and local data are tributaries of global
data. Given that any policy or guideline has to be changed
constantly with the evolution of the pandemic and that they
have significant public health and resource ramifications,
reliance on robust and accurate data is crucial. The aim of
this study, therefore, was to demonstrate how departments of
pathology and clinical care teams can play a broader healthcare
role by analyzing and describing the patterns of utilization of
healthcare variables. Although the focus of the study was on
COVID-19, the approach is applicable to other health problems
for which we need to understand the interaction of science,

Healthcare demands and the infrastructure required to
meet those demands have become increasingly complex in
modern times. In fact, these have radically changed during
the coronavirus disease 2019 (COVID-19) pandemic, especially
during the peaks or surges. To date, over 535 million cases and
over 6.3 million deaths have been recorded (The Johns Hopkins
Coronavirus Resource Center1 [Accessed 13 June 2022]). In
Africa, although it initially appeared that the disease had an
attenuated course in terms of cases and mortality, the impact is
by no means insignificant (1–4). Since the definition of the first
COVID-19 case in Kenya, March 2020, five waves have occurred,
resulting in over 5,600 deaths (Ministry of Health, Republic of
Kenya2 [Accessed 13 June 2022]). Similar to global observations,
the implications of these surges have been a massive influx of
COVID-19 patients, some of whom required intensive care,
marked pressure on pathology services, delivery of nursing
care, supply of therapeutics, excess mortality, and a plethora of
downstream healthcare needs generated by the pandemic (5–8).
From a pathology perspective, the sheer number of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests,
in the form of reverse transcription polymerase chain reaction
(RT-PCR), in combination with all the logistical complexities
of high volume sample and reagent management, introduced
enormous pressure in laboratories. Important to note that, in
low- and middle-income countries (LMICs), particularly in
Africa, only a few laboratories had existing molecular diagnostic
capacity, and hence, these had to be developed in record
time to meet the clinical demand for testing (9, 10). There
was also a ripple effect in all disciplines of pathology; clinical
chemistry, microbiology, hematology, and anatomic pathology.
A South African study looking at the short-term effects of
test ordering coming from routine follow-up of patients with
communicable and non-communicable diseases (NCDs) noted
a significant drop (up to 80% for some tests), in orders
for creatinine, lipids, HbA1c, thyroid-stimulating hormone
(TSH), and free triiodothyronine (fT3), as a consequence of
lockdown (11). Another study observed increased ordering of
procalcitonin and lactate dehydrogenase, driven by a clinical
demand for prognostication purposes. On the contrary, volumes
in hematology and virology declined (12). In South Australia,
a decline in almost all pathology tests except for molecular
microbiology was noted. In particular, troponin, a marker of
acute coronary syndrome (ACS) care, declined, begging the
question of whether this was caused by a reduced incidence of
ACS or because of hospital avoidance (13).
Prescription drug utilization also changed during the
pandemic, and a particular note has been made of antibiotics:
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policy, socioeconomic factors, and health-seeking and delivery
behavior in Africa.

the pharmacy, monthly clustered tallies of issued prescriptions
for azithromycin, dexamethasone, tocilizumab, enoxaparin,
fentanyl, remdesivir, and piperacillin/tazobactam (PIPZO) were
retrieved. These drugs were selected based on the perceived
changes that would occur in their utilization. As highlighted
in the introduction, dexamethasone, remdesivir, and other antiinflammatory agents were variably adopted for the management
of severe COVID-19. In addition, we were also keen on knowing
what the trends of antibiotic utilization would be, and therefore,
we included azithromycin and PIPZO in our analysis. We did
not delve into the area of rational antibiotic use in this paper.
Pharmacy data were retrievable from 2020, and, hence for
baseline, data for 3 months prior to the full-blown pandemic
in the country (January to March 2020) were used. From the
nursing department, we obtained bed occupancy for COVID-19
patients including the intensive care unit (ICU).

Materials and methods
Study setting and design
This was a cross-sectional, multidisciplinary study including
the departments of Pathology, Nursing, and Pharmacy, at the
Aga Khan University Hospital, a 280 bed tertiary, teaching, and
referral hospital in Nairobi, Kenya. A temporary field hospital
was set up to increase the capacity for taking care of COVID19 patients, and this brought the bed capacity for COVID-19
patients to 88, of which 11 were ICU beds. Our objective was to
explore data analytics for describing the patterns of healthcare
utilization using indicators from the laboratory, pharmacy, and
clinical care teams in an integrated fashion. The rationale for
the study was that such utilization patterns would not only
feed into larger national and international data sets that are
used for modeling and projections but would also be critical
in planning for near and intermediate future healthcare needs.
Although the focus was on data around COVID-19, the bigger
picture we envisioned was that African countries would use a
similar approach to develop additional tools for a more efficient
allocation of scarce health resources and improved healthcare
operations. Given that many health problems, from seasonal
infections to cancer and to metabolic diseases, that come to the
attention of healthcare workers be they physicians or nurses will
require a laboratory test and/or prescription, a steady source of
data is guaranteed.

Data analysis
Laboratory data were in the form of raw numbers of
each test performed and were clustered in monthly tallies.
The institutional COVID-19 positivity rate was continuously
monitored as a 7-day rolling positivity rate. In this manuscript,
this was collapsed into a monthly rolling positivity rate.
Pharmacy data were also collected as monthly tallies; however,
due to the multiple dosage formulations available for each drug,
standardized units were created. As an example, dexamethasone
may exist in 2, 4, or 6 mg formulations, and to standardize, all
issued doses were converted to 6 mg units. The standardized
units for the other prescription drugs were as follows:
enoxaparin, 80 mg; azithromycin, 500 mg; remdesivir, 100 mg;
tocilizumab, 80 mg; PIPZ0, 4.5 g; fentanyl, 100 mcg. From the
clinical care teams, daily censuses for in-patient and ICU
COVID-19 patients were collected and monthly averages were
calculated. Data analysis and visualization were performed
using Microsoft Excel version 16 (Microsoft Corporation) and
RStudio, running R software for data analysis, version 4.1.2
(Boston, MA). The monthly mean number of tests for each
of the selected tests in 2020 and 2021 was compared to the
corresponding baseline mean (2019 data). To determine the
statistical difference in the means, a t-test (unpaired and unequal
variance) was calculated, and p-values < 0.05 were considered
to be statistically significant. With regard to prescription drugs,
the relationship between the number of units for each drug
was plotted against the COVID-19 positivity rate, and nonlinear regression models were created. Best fit models were
determined using visual inspection and partial F-test compared
to the linear model, whereby p-values > 0.05 were considered
to significantly improve model fit. Finally, the COVID-19
positivity rate was plotted superimposed over percentage ICU
hospitalization trends, selected laboratory tests, and prescription
drug utilization.

Data retrieval
We began by developing a list of both laboratory tests and
prescription drugs whose turnover was perceived or projected to
change as the pandemic evolved. These included those that were
flagged for stock outs, on the one extreme, or as slow-moving
on the other. From the existing hospital information system,
queries to extract raw data were generated. The time frame was
March 2019 to December 2021, with 2019 pre-pandemic data
serving as a baseline, and 2020 to 2021 as 2 years of ongoing
COVID-19 pandemic data. Laboratory data retrieved were
monthly clustered tallies for tests including malaria parasite,
D-dimer, fibrinogen, C-reactive protein (CRP), procalcitonin,
serum sodium, HbA1C, HIV viral load, blood group, blood
count, cervical smear (PAP smear), histology, blood culture,
Mycobacterium tuberculosis (MTB), rifampicin (RIF) resistance
(MTB/RIF), SARS-CoV-2, RT-PCR, and summation of all
laboratory tests. The list of tests was representative of all
sections of the laboratory: clinical chemistry, hematology, blood
bank, microbiology, molecular, and histology. Similarly, from
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restrictions both in the first and second year of the pandemic.
These were thought to be caused by an increased utilization
related to the clinical management of COVID-19. Included in
this group were D-dimer, fibrinogen, CRP, and HbA1c. Tests
for D-dimer, for instance, increased by more than four times
from 2019 to 2021, an average of 114 to 525 (p-value <0.001).
Orders for HbA1c initially showed a modest increment in 2020,
but this rose by an average of 428 tests (95%CI: 346.6–508.2; pvalue <0.001), translating to a 38.4% increment. Figure 2 and
Table 1 show the graphical visualization and statistical analysis
of the changes in the monthly test volume means in 2020 and
2021 compared to the baseline (2019).
Pharmacy data also revealed a gradual to sharply increased
utilization of the selected prescription drugs. As visualized in
Figure 1, the utilization of dexamethasone, tocilizumab, and
remdesivir peaked during the third (Alpha variant) and fourth
(Delta variant) waves that saw positivity rates of 28.1 and
16.8%, respectively. Although there was an increase in utilization
during the Omicron variant wave, which had the highest
positivity rate (42.6%), it was still less compared to the previous
two waves. The models for prescription drug utilization during
the 2 years followed a non-linear regression model in relation
to the positivity rate as shown in Figure 3. Oral dexamethasone,
tocilizumab, enoxaparin, azithromycin, and remdesivir best fit
a quadratic model (polynomial regression, degree four). The
models were better than the linear models, with a partial Ftest showing significant p-values ranging from 0.045 in the
case of remdesivir to <0.0.001 in the case of enoxaparin, and
the R2 values ranged from 0.31 in the case of PIPZO to
0.72 in the case of azithromycin. The regression for PIPZO
best fit a cubic model; however, this was not any better than
the linear model (p-value 0.6). Fentanyl (model not shown)
best fit a quadratic model but was only marginally significant
(p-value 0.036). The model for intravenous dexamethasone,
unlike oral dexamethasone, was only marginally significant (pvalue 0.047) on a cubic model (model not shown). In this
study, we did not distinguish usual-care thromboprophylaxis
from therapeutic-dose anticoagulation in regard to enoxaparin.
The antibiotic PIPZO, typically used in the ICU setup,
remdesivir, fentanyl, an anesthetic adjunct, showed weak
predictive models. Tocilizumab, whose utilization was low in
pre-COVID-19 times, increased with rising cases. A common
feature noted for the pharmacologic agents was that the
utilization was highest between March and August 2021, when
Alpha and Delta were the predominant circulating variants.
By the end of December 2021 which was the cutoff for
our data collection, the Omicron wave was still ongoing
and was the highest in terms of the number of cases and
positivity rate. This was, however, characterized by a markedly
reduced utilization, compared to the previous waves. The
impact of the Omicron variant wave may therefore not be
fully evident.

This study was approved by the Institutional Ethics
Review Committee of Aga Khan University Hospital, Nairobi
[2021/IERC-87(v2)]. The study only looked at institutional data
sets from the health and laboratory information system. Patient
information, charts, records, or samples were not the subject of
this study, nor were they investigated.

Results
By December 2021, close to 118,000 SARS-CoV-2 PCR
tests had been performed. Five distinct waves with the zenith
points in the months of July 2020, November 2020, March
2021, August 2021, and December 2021 occurred as shown in
Figure 1. The characteristics of this trend matched very well
with the national tracking which contained a larger sample size,
giving external validity to the data set. Genomic epidemiology
studies in the country revealed that the first two waves were
predominantly caused by the original SARS-CoV-2 strain, while
the third, fourth, and fifth were caused by the Alpha, Delta, and
Omicron variants, respectively (20). The trend of the percentage
of patients in ICU generally followed the positivity rate with
less accentuated peaks. The initial ICU proportion in March and
April 2020 was high (33%). This was thought to be due to the
relatively small number of COVID-19 patients at the beginning
of the pandemic, as opposed to overrunning of the bed capacity.
Analysis of laboratory tests revealed two major groups. The
first was those whose test volumes decreased in the first year
(2020) and then rose in the following year. Some recovered
only marginally, but others to a level near the baseline, or in
a few cases, surpassing the baseline. Included in this group
malaria parasite test, MTB/RIF, blood group, blood count, and
histology showed a statistically significant decrease. Blood count,
a test included in diagnostic investigations, decreased by 15%,
an average of 1,814 tests (95%CI: 397.2–3229.6; p-value 0.016).
This was followed by only 6% growth for this test in 2021
compared to 2019 which was not statistically significant. On
the contrary, the monthly average tests for malaria in 2020
decreased by 480 tests (95%CI: 218.9–740.4; p-value 0.001),
translating to a 40.2% decline from 2019. This decrease persisted
and was still statistically significantly lower than in 2019 (pvalue <0.001). Other tests which showed a decrease, although
not statistically significant, were serum sodium, PAP smear,
blood culture, HIV viral load, and all laboratory tests summed
together. The majority of these test orders showed variable
recovery in 2021; however, test numbers for malaria and blood
groups showed negligible recovery. The immediate explanation
for this group was the restrictions implemented to control
the spread of COVID-19 resulting in hospital avoidance. The
second group was those whose test volumes increased despite
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FIGURE 1

Compound plot showing the trends in the positivity rate and proportion of patients in ICU as line graphs on the right vertical axes. The
movement prescription drugs and laboratory tests are plotted on the left vertical axes using bar charts in (A,B), respectively. The prescription
drug scale is log10 transformed. The horizontal axis (time series from March 2020 to December 2021) is common for the vertically aligned plots
(ICU, intensive care unit; CRP, C-reactive protein). Annotation in numbered squares: (1) Impositions of restrictions and curfew, (2) start of
vaccination and rise of predominantly Alpha variant, (3) Delta variant wave, (4) Lifting of restrictions and curfew, (5) Omicron variant wave.
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FIGURE 2

Figure of box-and-whisker plot (A–I) representing C-reactive protein, D-dimer, ﬁbrinogen, HBA1c, HIV viral load, Malaria parasite test, MTB/RIF,
PAP smear, and all laboratory tests. Each panel shows the changes in average tests per month (Av. Tests/mo) from 2019 to 2021 The mean is
represented by the orange dot. The statistical summaries of these and other tests not plotted are shown in Table 1.

Discussion

pattern for the malaria parasite test was perhaps an example
where restricted movement changed testing demand and, by
extrapolation, disease epidemiology. Nairobi, which is the
county the study was conducted in, is not endemic to malaria
(22). Typically, people contract malaria when they travel to
malaria endemic counties, and therefore, a restricted movement
was likely to lead to the further reduced incidence in Nairobi
and hence reduced testing requirements. This observation may
not be true for malaria endemic regions and for other diseases
endemic in distinct geographic distributions.
There is no doubt that social restrictions were beneficial in
managing COVID-19 patient numbers, especially until other
interventions, such as vaccines, were widely available. However,
one can see the potential negative effect of loss of continuity
in care due to prolonged restrictions, for example, diseases
such as tuberculosis (TB) and HIV whose prevalence in Africa
is still high. Initial diagnosis and follow-up rely heavily on
MTB/RIF and HIV viral load testing, and any lapse in the
diagnosis, treatment, or follow-up would lead to loss of the
benefits accumulated by the TB and HIV control programs (23).
A study conducted in Nairobi, Kenya, implemented real-time
monthly surveillance of TB and HIV activities to counteract
the feared negative impact on TB and HIV programs. Small
successes in treatment, follow-up, and referral were registered,
showing the usefulness of more active intervention (24). This

Laboratories regularly use data on test volumes and results
to determine among other laboratory operations, reagent
management, and workflow. The same is true for other
departments in a healthcare facility whose aims are to meet
the demands of testing, diagnosis, treatment, or prevention.
These data, if carefully analyzed, may, however, be utilized for
optimizing healthcare operations at a public health level. In
this study, we have demonstrated that there was significant
upward demand for CRP, fibrinogen, D-dimer, and HBA1c
test in relation to rising cases and care of COVID-19 patients.
Other laboratory tests were variably affected potentially due
to social–economic factors. The demand for COVID-19related therapeutics was best predicted by quadratic regression
models. The highest demand for both tests and therapeutics
was recorded during the Alpha and Delta variant waves of
the pandemic.
One finding that has also been observed by other
investigators was that interventions influenced by social political
and public health concerns determined health-seeking behavior
during the pandemic. Various degrees of restrictions and
lockdowns likely lead to loss of income, hospital avoidance,
fear of contracting COVID-19, postponement of elective
surgical cases, and restricted travel (8, 21). In our study, the
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TABLE 1 Table showing analysis of the changes in laboratory test in 2020 and 2021 compared to 2019 data.

2019
Test
D-dimer
Fibrinogen
Malaria

2020

Monthly mean (Range)

Mean (Range)

1 Mean [CI 95%]

114 (83–135)

355.8 (89–849)

5.9 (3–11)

14 (6–22)

2021
t-statistic (P-value)

Mean (Range)

1 Mean [CI 95%]

t-statistic (P-value)

+240.8 [65.3–416.3]

3.02 (0.01)

525 (207–1187)

+411 [229.6–592.4]

4.98 (<0.001)

+8.1 [4.4–11.8]

4.64 (<0.001)

22.2 (9–33)

+16.3 [11.4–21.1]

7.16 (<0.001)
6.41 (<0.001)

1192.3 (983–1489)

712.7 (334–1,683)

−479.6 [218.9–740.4]

3.93 (0.001)

747.3 (478–1,098)

−445 [301.1–589.1]

2401.8 (2,113–2,829)

2,712 (1,453–4,281)

+310.2 [0–225.2]

1.26 (0.23)

4186.9 (3,136–5,727)

+1785.1 [1268.3–2,302]

7.5 (<0.001)

1111.6 (928–1,239)

1204.1 (624–1,497)

+92.5 [0–72.2]

1.20 (0.25)

1,539 (1,401–1,723)

+427.4 [346.6–508.2]

10.97 (<0.001)

Cervical smear

553.6 (380–848)

430.6 (202–907)

−123 [0–262.5]

1.83 (0.08)

492.3 (402–721)

−61.3 [0–165.4]

1.24 (0.23)

MTB/RIF

144.8 (117–175)

111.2 (72–175)

−33.6 [6.6–60.6]

2.62 (0.02)

131.7 (93–159)

−13.1 [0–31.2]

1.49 (0.14)

HIV viral load

99.6 (79–129)

94.6 (72–131)

−5 [0–19.3]

0.72 (0.48)

109.8 (92–131)

+10.2 [0–2.2]

1.71 0.10

Serum Sodium

5242.3 (4,849–5,813)

4712.8 (2,339–5,631)

−529.5 [0–1,060]

2.15 (0.05)

5607.9 (5,104–6,587)

+365.6 [38.7–692.4]

2.36 (0.030)

Procalcitonin

736.4 (84–1,071)

733.8 (397–1,025)

−2.6 [0–185.2]

0.03 (0.98)

916.9 (616–1,289)

+180.5 [0–16.4]

1.90 0.07

Blood group

388 (333–441)

324.5 (229–520)

−63.5 [15.4–111.6]

2.83 (0.013)

353.8 (315–387)

−34.2 [11.9–56.4]

3.19 (0.004)

Blood count

11717.8 (10,660–14,100)

9904.3 (6,247–13,098)

−1813.5 [397.2–3229.6]

2.74 (0.016)

12479.5 (10,448–16,766)

+761.7 [0–445.6]

1.34 (0.19)

Blood culture

457.8 (428–518)

415.5 (279–578)

−42.3 [0–95.5]

1.71 (0.11)

484.1 (426–621)

+26.3 [0–13.2]

1.41 (0.17)

C-reactive protein
HbA1C

07

Histology
All lab tests

1407.9 (1,173–1,668)

1254.3 (785–1,450)

−153.6 [10–296.8]

2.23 (0.037)

1374.7 (1,179–1,658)

−33.2 [0–157.5]

0.55 (0.58)

159,385 (144,776–182,872)

143416.3 (86,696–177,800)

−15968.8 [0–34,165.3]

1.89 (0.08)

179385.2 (157,600–226,159)

+20000.2 [6945.2–33055.1]

3.24 (0.005)

The monthly mean test numbers and range for each year are shown. The differences in mean (1 Mean) have been calculated, and increase or decrease compared to 2019 is depicted using (+) or (–) symbols, respectively. To test for statistical significance
in the change, unpaired t-test, assuming unequal variance was applied. The t-statistic, corresponding 95% confidence interval (CI 95%), and p-values are presented. The last row (All lab tests) represents the monthly mean number of all tests performed
in the laboratory including those not analyzed individually.
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FIGURE 3

Figure showing the relationship between positivity rate and monthly prescription drug utilization. (A–F) represent the models for azithromycin,
oral dexamethasone, enoxaparin, piperacillin/tazobactam (PIPZO), remdesivir, and tocilizumab, respectively. The models are non-linear, and
polynomial regression best ﬁtted a quadratic model with the exception of PIPZO, (D) which best ﬁtted a cubic model. The P-values for each
model shown are the outcome of partial F-test to determine whether there was a statistically signiﬁcant difference from the linear model. The
model for PIPZO was not signiﬁcant. Not shown, are models for fentanyl (quadratic model, p-value 0.03) and intravenous dexamethasone (cubic
model, p-value 0.04).
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The study was limited by the lack of patient-level integration
and analysis of the results of tests included in this study.
The trends of test positive MTB/RIF, malaria, or out-of-range
HbA1c, for instance, would provide more granular data on
the translation of diagnostics to clinical care and treatment.
In addition, data on which patients had what test, for what
diseases, and what treatment was given would provide key
information on the extent to which healthcare needs are met by
a particular program, assess adherence to good clinical practice,
and facilitate national healthcare planning. Furthermore, this
was a targeted analysis; we only looked into a small subset of
pathology, pharmacy, or nursing outputs. A comprehensive and
unbiased analysis would, of course, require more sophisticated
computational capacity. Although this was a targeted, singleinstitution study, we assume that we have demonstrated the
power of integrated data analysis would have, when applied
at a national level for the purposes of healthcare planning
in Africa.
Data analytics has become a major tool in the study
of global social and economic matters. Laboratories produce
vast amounts of data; unfortunately, most of these data lie
unanalyzed and therefore unusable by the community. These
data are not only important for the estimation of disease
prevalence but can also be indicators of access to treatment,
follow-up, and unmet clinical needs. For example, during
the first two waves, stock outs of laboratory reagents and
consumables disrupted operations and by extension clinical
care. This was occasioned by the abrupt changes in demand
for tests outlined above combined with the need to process
large numbers of COVID-19 tests. We, therefore, utilized
the data we had collected, and the national epidemiological
projections to inform the projected third wave. This prompted
a targeted stocking of essential drugs, laboratory, reagents,
and consumables resulting in better preparedness, a significant
reduction in stock outs, and reduced disruptions in testing and
healthcare delivery in the subsequent waves.
The results of this study inform us of the expected scenario
in the event of other outbreaks with similar pathophysiology as
COVID-19. Furthermore, they lead us to recommend increased
efforts at diabetes screening, cervical cancer screening, and
cancer screening as well as active follow-up of HIV and TB
patients who may have discontinued follow-up. Harnessing data
analytics is probably as important as investing in technology and
human resource to improve pathology in Africa. With regard
to future prospects, the wealth of information from this limited
analysis makes a strong case for expanding its scope. The data
that we have collected and analyzed will be an excellent resource
for pathology and other clinical departments since other health
data analytical projects can plug into this base, and the process
can be amplified by multicenter partnerships. This will also
be a stepping stone to “big data” analysis which is promising
enormous potential even in healthcare (31). Investing in data

trend and potential intervention may also apply to cervical
cancer screening which is dependent on PAP smears and
human papillomavirus (HPV) testing. In the majority of African
countries, screening uptake is already suboptimal, and this is in
addition to East Africa having the highest cancer of the cervix
disease burden (25). Loss of screening momentum is therefore
a drawback in reducing the incidence of invasive cancer of
the cervix. A late-stage cancer diagnosis is also a recurring
health problem but is likely more common in Africa (26, 27).
Therefore, decreased histology services could potentially mean
delayed surgeries and diagnosis including cancer diagnosis and
a worsening of late the stage cancer diagnosis problem.
Another pattern of interest was HbA1c testing. Testing for
HbA1c is typically performed as a diagnostic test for diabetes or
to monitor glycemic control over the last 3 months. Increment
in HbA1c testing appears to be intuitive, given the fact that
diabetes is a leading risk factor for severe COVID-19. However,
the rapid rise points to COVID-19 unmasking a significant
population with undiagnosed diabetes in the community. In a
recent publication from our institution, including 913 records
of admitted patients, the proportion of COVID-19 patients
with diabetes at baseline was 27.3% and this rose by over 20%
over the course of admission, bringing the proportion with
diabetes to 48.1% (28). Given that glucocorticoids are essential
for hospitalized patients with COVID-19, pre-diabetics who
were tipped over to overt diabetes may have contributed to
this proportion.
The interaction between pathology, pharmacy, and clinical
care needs clearly emerged in our analysis. Hemostasis appears
to have been a major issue given the simultaneous rise in
prescriptions for enoxaparin and increased demand for
fibrinogen and D-dimer test especially when hospitalization
was high. Inflammation and immune dysregulation also were
critical areas given the concurrent rise in inflammatory marker
testing (CRP and procalcitonin) and inflammation modifying
agents (dexamethasone and tocilizumab). Notable was the
relatively modest increase in the utilization of prescription
drugs during the Omicron variant wave which was the highest
in terms of positivity rate. This provided some evidence that the
Omicron variant was associated with less severe disease than the
previous variants, with contributing factors being vaccination
and immunity acquired via natural infection (29, 30). This
observation should, however, be interpreted with the caveat that
the impact of the Omicron variant may not have fully emerged
since this wave was still ongoing at the cut-off time for our data
collection. At an operations level, this pattern of decreasing
utilization means that the demand for drugs used for COVID19 patients and tests pushed up by COVID-19-related testing
would decrease. Rationally, one would commensurately
decrease procurement to avoid the other extreme
problem of overstocking and expiry leading to healthcare
resource wastage.
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information systems that can be seamlessly interlinked with
other clinical public health departments, real-time analytics, and
contributing to policy formulation will be a double-edged sword
that would enable pathology departments to exert a broader
impact in public healthcare.
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